Emtricitabine

NOT RECOMMENDED AS AN ESSENTIAL MEDICINE

Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.2. Antiretrovirals > 6.4.2.1. Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

EMLc | Codes ATC: J05AF09

Indication	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified Code ICD11: 1C62.Z
INN	Emtricitabine
Type de médicament	Chemical agent
Type de liste	Liste de base
Additional notes	Emtricitabine (FTC) is an acceptable alternative to lamivudine (3TC), based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals.
Formulations	**Oral > Liquid:** 10 mg per mL **Oral > Solid:** 200 mg
Historique des statuts LME	Ajouté pour la première fois en 2007 (TRS 946) Modifié en 2007 (TRS 950) Retiré en 2015 (TRS 994)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Limite d'âge	>3 months
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Wikipédia	Emtricitabine
DrugBank	Emtricitabine

Résumé des preuves et recommandation du comité d'experts

The Expert Committee recommended the removal of emtricitabine from the EML and EMLc on the basis that listing is not aligned with dosing guidelines in the 2013 WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (1), and also because of the availability of fixed-dose combination formulations containing emtricitabine. References: 1. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.

